✦ LIBER ✦

Potential Predictive Value of Bcl-2 for Response to Tamoxifen in the Adjuvant Setting of Node-Positive Breast Cancer

✍ Scribed by Fatima Cardoso; Marianne Paesmans; Denis Larsimont; Virginie Durbecq; Chantal Bernard-Marty; Ghizlane Rouas; Stella Dolci; Christos Sotiriou; Martine J. Piccart; Angelo Di Leo

Book ID: 115075646
Publisher: CIG Media Group, LP.
Year: 2004
Tongue: English
Weight: 136 KB
Volume: 5
Category: Article
ISSN: 1526-8209
DOI: 10.3816/cbc.2004.n.043

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic value of HER-2/neu and p53 ex

Prognostic value of HER-2/neu and p53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment

✍ M.A. Climent; M.A. Seguı́; G. Peiró; R. Molina; E. Lerma; B. Ojeda; J.J. López-L 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 219 KB

PCN41 COST-EFFECTIVENESS OF TAC VERSUS F

PCN41 COST-EFFECTIVENESS OF TAC VERSUS FAC FOR THE TREATMENT OF NODE POSITIVE BREAST CANCER IN THE ADJUVANT SETTING

✍ M Fonseca; G Araujo; E Saad; R Uehara 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Change in Expression of ER, bcl-2 and MI

Change in Expression of ER, bcl-2 and MIB1 on Primary Tamoxifen and Relation to Response in ER Positive Breast Cancer

✍ Frances S. Kenny; Peter C. Willsher; Julia M.W. Gee; Robert I. Nicholson; Sarah 📂 Article 📅 2001 🏛 Springer US 🌐 English ⚖ 105 KB

Influence of circulating c-erbB-2 serum

Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients

✍ Tanja Fehm; Peter Maimonis; Stephen Weitz; Yosh Teramoto; Alexander Katalinic; W 📂 Article 📅 1997 🏛 Springer US 🌐 English ⚖ 37 KB

Cost-effectiveness analysis of trastuzum

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

✍ Louis P. Garrison Jr; Deborah Lubeck; Deepa Lalla; Virginia Paton; Amylou Dueck; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

## Abstract ## BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. A cost‐effectiveness analysis was performed to assess clinical and economic implications of adding t

Prognostic and predictive value of TFF1

Prognostic and predictive value of TFF1 for adjuvant endocrine therapy in Chinese women with early ER positive breast cancer: Comparing aromatase inhibitors with tamoxifen

✍ Liheng Zhou; Tingting Yan; Yiwei Jiang; Genhong Di; Zhenzhou Shen; Zhimin Shao; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 318 KB